A multicenter, real ‐world study on effectiveness and safety of first‐line modified PD‐1 inhibitors with chemotherapy in advanced non‐small cell lung cancer (aNSCLC) with drive gene‐negative
ConclusionsThe modified PD-1 inhibitors showed comparable survival outcomes and manageable safety profiles in NSCLC compared to Pembrolizumab. Moreover, these inhibitors exhibited improved accessibility and economic outcomes compared to Pembrolizumab. While there were similarities in drug-related and immunotherapy-related adverse reactions between the modified PD-1 inhibitors and Pembrolizumab, there were some slight differences. Further prospective and retrospective studies would be necessary to validate these findings beyond the scope of the CTONG1901 study.
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tao Li,
Chao Chen,
Lu Liu,
Jiapei Qin,
Lupeng Qiu,
An Wang,
Weiwei Dong,
Gehan Zhang,
Yao Li,
Lei Zhao,
Fan Zhang,
Yi Hu Tags: RESEARCH ARTICLE Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Genetics | Immunotherapy | Lung Cancer | Non-Small Cell Lung Cancer | Statistics | Study